Sign Up Now!
To sign up for our newsletter or print publications, please enter your contact information below and click "Subscribe".
First Name
*
Last Name
*
Email Address
*
Email Address (Verify)
*
TOP
Print Edition
We will request your mailing address on the next page.
TOP
E-Newsletters and Communications
JHOP
Print Edition
We will request your mailing address on the next page.
JHOP
E-Newsletters and Communications
I have reviewed and consent to the terms of
TOP
's
Privacy Policy
, and
TOP
has my permission to retain my information in its database, and to forward pertinent communications to me.
Home
Issues
2021
January 2021 - Vol 14 No 1
2020
November 2020, Vol 13, No 6
September 2020 - Vol 13 no 5
July 2020 - Vol 13 no 4
May 2020 - Vol 13 no 3
March 2020 - Vol 13 no 2
January 2020 - Vol 13 No 1
2019
November 2019 - Vol 12 No 4
August 2019 - Vol 12 No 3
May 2019 - Vol 12 No 2
February 2019 - Vol 12 No 1
2018
November 2018 - Vol 11 No 3
August 2018 - Vol 11 No 2
May 2018 - Vol 11 No 1
Issue Archive
Special Issues
Supplements
ASK THE EXPERT: First-Line Treatment of Metastatic Non-small cell Lung Cancer
Guide to New FDA Approvals
2019 Fourth Annual Guide
2018 Third Annual Guide
2017 Second Annual Guide
2016 First Annual Guide
Categories
Conference Correspondent
Year End Review 2019
Web Exclusives
Ovarian Cancer Overview
All Web Exclusives
Drug Updates
FDA Approvals, News & Updates
In the News
Interview with the Innovators
Press Releases
Online First
Media Library
Videos
Audiocasts
Quick Quiz
CE
About
About TOP
Advertise
Editorial Board
Contact Us
Resources
Submit
Author Guidelines
Combination Therapy as Maintenance in Ovarian Cancer
Videos
-
Interview with the Innovators
,
Video
Amina Ahmed, MD, Paula Anastasia, RN, MN, AOCN, and Ali McBride, PharmD, MS, discuss the benefits and risks of using combination therapy with a PARP inhibitor and bevacizumab as first-line maintenance therapy in ovarian cancer.
Related Items
An Expert Perspective on the Current and Future of Maintenance Therapy in Ovarian Cancer
Amina Ahmed, MD
,
Paula Anastasia, RN, MN, AOCN
,
Ali McBride, PharmD, MS, BCPS
Videos
published on
November 30, 2020
in
Interview with the Innovators
,
Video
Immunotherapy in Combination with PARP Inhibitors as First-Line Maintenance Therapy in Ovarian Cancer
Amina Ahmed, MD
,
Paula Anastasia, RN, MN, AOCN
,
Ali McBride, PharmD, MS, BCPS
Videos
published on
November 13, 2020
in
Interview with the Innovators
,
Video
Adverse Events and Improvements in Quality of Life Associated with First-Line Maintenance Therapy in Ovarian Cancer
Paula Anastasia, RN, MN, AOCN
,
Ali McBride, PharmD, MS, BCPS
Videos
published on
November 2, 2020
in
Interview with the Innovators
,
Video
Management of Adverse Events Associated with PARP Inhibitors as First-Line Maintenance Therapy in Ovarian Cancer
Ali McBride, PharmD, MS, BCPS
,
Paula Anastasia, RN, MN, AOCN
Videos
published on
October 11, 2020
in
Interview with the Innovators
,
Video
Clinical Data on First-Line Maintenance Therapy in Ovarian Cancer
Amina Ahmed, MD
,
Ali McBride, PharmD, MS, BCPS
,
Paula Anastasia, RN, MN, AOCN
Videos
published on
September 15, 2020
in
Interview with the Innovators
,
Video
Choosing Among PARP Inhibitors as Maintenance Therapy in Ovarian Cancer
Amina Ahmed, MD
,
Ali McBride, PharmD, MS, BCPS
,
Paula Anastasia, RN, MN, AOCN
Videos
published on
September 8, 2020
in
Interview with the Innovators
,
Video
Choosing Maintenance Therapy in Ovarian Cancer
Amina Ahmed, MD
,
Ali McBride, PharmD, MS, BCPS
,
Paula Anastasia, RN, MN, AOCN
Videos
published on
August 18, 2020
in
Interview with the Innovators
,
Video
A Review of Clinical Trials Suggesting the Use of PARP Inhibitors as First-Line Maintenance Therapy in Ovarian Cancer
Amina Ahmed, MD
,
Ali McBride, PharmD, MS, BCPS
,
Paula Anastasia, RN, MN, AOCN
Videos
published on
August 11, 2020
in
Interview with the Innovators
,
Video
Changes in HRD “Fingerprints” in Patients with Ovarian Cancer and Their Impact on Clinical Outcomes
Amina Ahmed, MD
,
Paula Anastasia, RN, MN, AOCN
Videos
published on
July 28, 2020
in
Interview with the Innovators
,
Video
The Impact of Germline or Somatic HRD Testing on Treatment Decisions in Ovarian Cancer
Ali McBride, PharmD, MS, BCPS
,
Paula Anastasia, RN, MN, AOCN
Videos
published on
July 14, 2020
in
Interview with the Innovators
,
Video
Last modified: October 6, 2020
Home
Issues
2021
January 2021 - Vol 14 No 1
2020
November 2020, Vol 13, No 6
September 2020 - Vol 13 no 5
July 2020 - Vol 13 no 4
May 2020 - Vol 13 no 3
March 2020 - Vol 13 no 2
January 2020 - Vol 13 No 1
2019
November 2019 - Vol 12 No 4
August 2019 - Vol 12 No 3
May 2019 - Vol 12 No 2
February 2019 - Vol 12 No 1
2018
November 2018 - Vol 11 No 3
August 2018 - Vol 11 No 2
May 2018 - Vol 11 No 1
Issue Archive
Special Issues
Supplements
ASK THE EXPERT: First-Line Treatment of Metastatic Non-small cell Lung Cancer
Guide to New FDA Approvals
2019 Fourth Annual Guide
2018 Third Annual Guide
2017 Second Annual Guide
2016 First Annual Guide
Categories
Conference Correspondent
Year End Review 2019
Web Exclusives
Ovarian Cancer Overview
All Web Exclusives
Drug Updates
FDA Approvals, News & Updates
In the News
Interview with the Innovators
Press Releases
Online First
Media Library
Videos
Audiocasts
Quick Quiz
CE
About
About TOP
Advertise
Editorial Board
Contact Us
Resources
Submit
Author Guidelines